Robinson Pharma unveils new brand-protection distribution policy

This reinforces the US manufacturer's commitment to safety, transparency, and strict supply chain standards.

With over 35 years of experience in the nutritional supplement and healthcare industry in the United States, Robinson Pharma has consistently prioritised the quality, safety, and reliability of its products.

Amid growing market challenges, including counterfeit goods, mislabelled products, and quality control failures, the company is actively working with industry partners to address fraudulent practices and protect consumer interests.

The team at Robinson Pharma is committed to crafting high-quality products with unmatched credibility

To address such challenges, the Robinson Pharma has conducted a comprehensive review of its client portfolio and terminated agreements with distribution and import partners who no longer align with the company's standards.

This measure not only protects the legitimate rights of consumers and partners but also ensures that any product bearing the firm's brand or using its ingredients meets strict criteria for quality, safety, and origin.

Robinson Pharma has not engaged in direct business operations in the Vietnamese market since 2014. Instead, the company functions as a contract manufacturer, producing goods to order for local partners, such as pharmacies and health food companies, who then supply the end consumers.

The company operates a single headquarters in California and has authorised global partners for product distribution; it does not have any branches of the same name in any other country.

Robinson Pharma has clarified that it bears no association with or liability for products bearing the brand's name or ingredients if sold outside its official distribution channels.

Furthermore, Robinson Pharma specialises exclusively in dietary supplements and healthcare products, and does not manufacture or distribute therapeutic drugs.

The company has no affiliation whatsoever with any businesses advertising or selling therapeutic drugs under the Robinson Pharma's name or claiming its origin.

From a modest beginning with just two manufacturing facilities in the early 2000s, Robinson Pharma has now grown to eight modern production facilities with over 850 employees

To safeguard their interests, Robinson Pharma strongly advises customers and partners to purchase products only from official distribution channels confirmed as partners. Information regarding product origin and the list of official distributors can be found on the company’s website.

Robinson Pharma is confident that these stringent control measures, in cooperation with its valued customers and partners, will help build a more transparent and secure market, effectively preventing counterfeit and imitation products.

The company remains steadfast in its commitment to delivering the highest quality products and services while resolutely protecting the rights of every customer.

Saudi Aramco targets Vietnam for refining and distribution During discussions with Vietnam’s Prime Minister Pham Minh Chinh, Saudi Aramco’s chairman and CEO, Amin H. Al-Nasser, underscored the company’s interest in expanding into Vietnam’s refining, petrochemical, and fuel distribution sectors.

Promoting pharma technology transfer with more policy support Experts have urged Vietnam to issue more support policies to facilitate technology transfer in pharmaceuticals and vaccine manufacturing, enabling it to achieve the ambitious goal of becoming a regional hub for the latest medication.

Citi Foundation announces 2025 Global Innovation Challenge to accelerate youth employability Fifty community organisations will receive a collective $25 million in catalytic funding, building on over a decade of Citi Foundation investment in youth, with requests for proposals underway until March 4.